Glycopyrronium bromide


Generic Medicine Info
Contraindications
Severe ulcerative colitis, obstructive disease of the gastrointestinal tract (e.g. achalasia, pyloroduodenal stenosis), paralytic ileus, intestinal atony in elderly or debilitated patients, toxic megacolon complicating ulcerative colitis, unstable cardiovascular status in acute haemorrhage, glaucoma, obstructive uropathy (e.g. bladder neck obstruction due to prostatic hypertrophy), myasthenia gravis. Acute deterioration of COPD. Concomitant use with solid oral KCl.
Special Precautions
Patient with CV disease (e.g. coronary artery disease, ischemic heart disease, ventricular failure, MI, long QT syndrome, tachyarrhythmia, heart failure, hypertension and tachycardia); autonomic neuropathy, hyperthyroidism, hiatal hernia with reflux esophagitis, ulcerative colitis and severe hypersensitivity to milk proteins. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor heart rate, anticholinergic effects, pulmonary function (e.g. FEV1, peak flow) of patients on inhalation.
Adverse Reactions
Significant: Drowsiness, blurred vision, constipation, intestinal pseudo-obstruction, heat prostration, diarrhoea, incomplete intestinal obstruction, urinary retention, bronchospasm, hypersensitivity reactions. Blood and lymphatic system disorders: Hypokalaemia, hypernatraemia. Cardiac disorders: Arrhythmia, palpitation, tachycardia. Gastrointestinal disorders: Abdominal pain, dry mouth, nausea, vomiting. General disorders and administration site conditions: Pyrexia. Infections and infestations: Upper respiratory tract infection, otitis media, UTI, influenza, pharyngitis streptococcal, pneumonia, sinusitis, gastroenteritis viral, nasopharyngitis, ear infection, cellulitis, oral herpes. Metabolism and nutrition disorders: Dehydration, dysgeusia. Nervous system disorders: Headache, dizziness. Psychiatric disorders: Behavioural changes, agitation, irritability, restlessness, insomnia. Renal and urinary disorders: Dysuria. Respiratory, thoracic and mediastinal disorders: Nasal congestion, reduced bronchial secretion, epistaxis. Skin and subcutaneous tissue disorders: Flushing, rash.
ROUTE(S) : IM / IV / Parenteral: B
ROUTE(S) : Inhalation: C
Drug Interactions
May enhance ulcerogenic effect of solid oral KCl. May increase antimuscarinic side effects with amantadine, antiarrhythmics (e.g. disopyramide), anticholinergics, TCA, MAOIs, antipsychotics (e.g. phenothiazine, clozapine, haloperidol), antiparkinsonian drugs, antispasmodics (e.g. domperidone, metoclopramide), and antihistamines. Reduced absorption of ketoconazole. May increase risk of severe constipation with opioid analgesics.
CIMS Class
Muscle Relaxants
ATC Classification
A03AB02 - glycopyrronium bromide ; Belongs to the class of synthetic anticholinergics, quaternary ammonium compounds. Used in the treatment of functional bowel disorders.
R03BB06 - glycopyrronium bromide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, anticholinergics.
Disclaimer: This information is independently developed by CIMS based on glycopyrronium bromide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in